BioAffinity Technologies Reports Growth Of 375% In CyPath Lung Tests Ordered And Processed Over The Past Three Months As Compared To The Previous Three Months
BioAffinity Technologies Reports Growth Of 375% In CyPath Lung Tests Ordered And Processed Over The Past Three Months As Compared To The Previous Three Months
Increasing physician interest, newly approved reimbursement code driving growth
医生兴趣增加，新批准的报销法推动增长
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, today reported accelerating growth of 375% in CyPath Lung tests ordered and processed over the past three months as compared to the previous three months. CyPath Lung is a noninvasive test to detect early-stage lung cancer.
生物技术公司BioAffinity Technologies, Inc.（纳斯达克股票代码：BIAF，BIAFW））是一家专注于早期癌症和肺部疾病检测需求的生物技术公司，今天报告称，与前三个月相比，过去三个月订购和处理的CyPath肺部测试加速增长了375％。CyPath 肺是一种无创性测试，用于检测早期肺癌。
bioAffinity Technologies is on target to meet its sales forecast for the previously announced limited test market launch in Texas designed to refine future positioning and strategic insight for CyPath Lung in preparation for expanding to the national market.
BioAffinity Technologies的目标是实现其先前宣布的在德克萨斯州推出的限量测试市场的销售预测，该计划旨在完善Cypath Lung的未来定位和战略洞察力，为向全国市场扩张做准备。
"The introduction of our reimbursement code, completion of our branding, and expansion of our sales force have markedly contributed to the growing physician interest and adoption of our innovative, noninvasive CyPath Lung test. Increasing physician satisfaction and adoption have also been driven by the successful integration and efficient operation of our commercial laboratory, Precision Pathology Laboratory," bioAffinity Technologies' President and CEO Maria Zannes said. "Importantly, our sales growth has been in line with our expectations and bolsters our confidence in our ability to capitalize on the lung cancer diagnostics market projected to reach $4.7 billion by 2030."
“我们的报销代码的引入、品牌的完善以及销售队伍的扩大，显著地促进了医生对我们创新的无创CyPath肺部检查的兴趣和采用。我们的商业实验室精密病理学实验室的成功整合和高效运营也推动了医生满意度和采用率的提高。” BioAffinity Technologies总裁兼首席执行官玛丽亚·赞内斯说。“重要的是，我们的销售增长符合我们的预期，增强了我们对我们利用肺癌诊断市场的能力的信心，预计到2030年肺癌诊断市场将达到47亿美元。”
Pulmonologists and other lung health specialists understand the critically important role of screening and early diagnosis in improving outcomes for those diagnosed with lung cancer and providing peace of mind for individuals at elevated risk of developing the disease. bioAffinity Technologies' commitment to noninvasive cancer detection is poised to reshape the landscape of lung health management by increasing early detection and treatment.
肺科医生和其他肺部健康专家明白，筛查和早期诊断在改善肺癌确诊者的预后以及让患病风险较高的人高枕无忧方面起着至关重要的作用。BioAffinity Technologies对无创癌症检测的承诺有望通过增加早期发现和治疗来重塑肺部健康管理格局。
bioAffinity Technologies will release financial results for the fourth quarter and full year ended December 31, 2023, on April 1, 2024.
BioAffinity Technologies将于2024年4月1日发布截至2023年12月31日的第四季度和全年财务业绩。
About CyPath Lung
关于 CyPath Lung
CyPath Lung uses advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath Lung incorporates a fluorescent porphyrin, TCPP, that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage cancer can improve outcomes and increase patient survival.
CyPath Lung 使用先进的流式细胞仪和人工智能 (AI) 来识别患者痰液中表明恶性肿瘤的细胞群。自动数据分析有助于确定是否存在癌症或患者是否没有癌症。Cypath Lung含有一种荧光卟啉TCPP，它优先被癌症和癌症相关细胞吸收。临床研究结果表明，对于肺结节小于20毫米的高风险患者，Cypath Lung检测肺癌的灵敏度为92％，特异性为87％，准确率为88％。诊断和治疗早期癌症可以改善预后并提高患者的存活率。
译文内容由第三方软件翻译。